24小时热门版块排行榜

返回列表

当前主题已经存档。

zlwcw

木虫 (著名写手)

应助: 1 (幼儿园)
金币: 2021.1
散金: 225
红花: 8
帖子: 1274
在线: 219.7小时
虫号: 530429
注册: 2008-03-21
性别: GG
专业: 代谢性疾病药物药理

[交流] 【其他】PPD完成收购保诺科技

With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China, making it the largest contract research organization to offer clinical development and discovery services in the country.

"Our acquisition of BioDuro positions us to capitalize on the tremendous growth in Asia Pacific and to become the CRO of choice in China," said David Grange, chief executive officer of PPD. "BioDuro has a premier reputation for delivering quality service and has built an exceptional team of researchers and scientists. We are very pleased to welcome BioDuro's 660 employees into PPD."

Founded in 2005, BioDuro operates a state-of-the-art, 110,000-square-foot laboratory in Beijing. With the vast majority of its employees based in China, the company focuses on providing fully integrated programs to synthesize and optimize novel compounds to generate drug development candidates.

PPD paid approximately $77 million in cash to acquire BioDuro.

As previously announced, PPD recently acquired Excel PharmaStudies, one of the largest contract research organizations in China, expanding PPD's Phase II-IV clinical, data management, biostatistics, regulatory and quality assurance services in this rapidly growing market. PPD has offices throughout Asia Pacific in addition to global central lab facilities in China and Singapore.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 38 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

PPD公司近日宣布，公司已完成对保诺科技（BioDuro LLC）的收购。保诺科技是一家致力于提供综合新药研发项目和服务的新药研发外包公司。

通过此次收购，PPD目前在亚太地区的员工总数超过1400人，其中近1000名员工在中国，使其成为该国最大的提供临床开发和新药研发服务的合同研究组织。

PPD的首席执行官David Grange说：“收购保诺科技使我们能够充分利用亚太地区巨大的增长机会，并成为中国市场上的首选合同研究组织。保诺科技的品质服务具有良好的声誉，并且拥有一支杰出的研究员和科学家团队。我们欣然欢迎保诺科技的660名员工加入PPD。”

保诺科技成立于2005年，在北京拥有一个11万平方英尺的尖端实验室。公司的绝大多数员工都在中国，公司致力于提供全方位的项目，通过新化合物的合成与优化制成备选研发药物。

PPD为收购保诺科技约支付了7700万美元现金。

根据此前的公告，PPD最近还收购了中国最大的合同研究组织之一依格斯医疗科技公司，在这个快速成长的市场中扩展了公司的二~四期系列临床业务、数据管理、生物统计，以及合规与质保服务。PPD在亚太地区设有多处办事处，并在中国和新加坡设有全球中心实验室。

PPD是一家领先的全球性合同研究组织，提供新药研发、开发和审批后服务以及综合性合作开发计划。我们的客户及合作伙伴包括制药、生物技术、医疗器械、学术及政府机构。PPD依靠在38个国家设立的分支机构和遍布全球的10,500多名专业人才，运用创新技术和专业治疗经验，秉承坚定的质量承诺，帮助客户及合作伙伴获得最大的研发投资回报，使安全有效的疗法更快应用于患者。

[ Last edited by zlwcw on 2010-3-13 at 13:26 ]

回复此楼